Literature DB >> 9272766

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors.

M Arnone1, J Maruani, F Chaperon, M H Thiébot, M Poncelet, P Soubrié, G Le Fur.   

Abstract

SR 141716, a selective central CB1 cannabinoid receptor antagonist, markedly and selectively reduces sucrose feeding and drinking as well as neuropeptide Y-induced sucrose drinking in rats. SR 141716 also decreases ethanol consumption in C57BL/6 mice. In contrast, blockade of CB1 receptors only marginally affects regular chow intake or water drinking. The active doses of SR 141716 (0.3-3 mg/kg) are in the range known to antagonize the characteristic effects induced by cannabinoid receptor agonists. These results suggest for the first time that endogenous cannabinoid systems may modulate the appetitive value of sucrose and ethanol, perhaps by affecting the activity of brain reward systems.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272766     DOI: 10.1007/s002130050326

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  156 in total

1.  The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine.

Authors:  Aaron N A Verty; Malini E Singh; Iain S McGregor; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2003-04-17       Impact factor: 4.530

2.  Differential effects of single versus repeated alcohol withdrawal on the expression of endocannabinoid system-related genes in the rat amygdala.

Authors:  Antonia Serrano; Patricia Rivera; Francisco J Pavon; Juan Decara; Juan Suárez; Fernando Rodriguez de Fonseca; Loren H Parsons
Journal:  Alcohol Clin Exp Res       Date:  2011-12-05       Impact factor: 3.455

Review 3.  The endocannabinoid system: role in energy regulation.

Authors:  Thomas F Gamage; Aron H Lichtman
Journal:  Pediatr Blood Cancer       Date:  2012-01       Impact factor: 3.167

4.  Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.

Authors:  Jason E Gallate; Paul E Mallet; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2003-12-09       Impact factor: 4.530

Review 5.  Neuroendocrine regulation of eating behavior.

Authors:  R Vettor; R Fabris; C Pagano; G Federspil
Journal:  J Endocrinol Invest       Date:  2002-11       Impact factor: 4.256

6.  The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin.

Authors:  Sonia A Tucci; Elizabeth K Rogers; Marta Korbonits; Tim C Kirkham
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

7.  Effects of CB1 and CRF1 receptor antagonists on binge-like eating in rats with limited access to a sweet fat diet: lack of withdrawal-like responses.

Authors:  Sarah L Parylak; Pietro Cottone; Valentina Sabino; Kenner C Rice; Eric P Zorrilla
Journal:  Physiol Behav       Date:  2012-07-06

8.  A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Authors:  N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

9.  Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.

Authors:  E K Jones; T C Kirkham
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

10.  Reduced sensitivity to reward in CB1 knockout mice.

Authors:  Carles Sanchis-Segura; Brandon H Cline; Giovanni Marsicano; Beat Lutz; Rainer Spanagel
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.